Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 May;70(823):329–343. doi: 10.1136/pgmj.70.823.329

Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants.

M J Kendall 1, I Rajman 1, S R Maxwell 1
PMCID: PMC2397611  PMID: 8016003

Full text

PDF
329

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991 Apr 18;324(16):1098–1104. doi: 10.1056/NEJM199104183241605. [DOI] [PubMed] [Google Scholar]
  2. Bergkvist L., Adami H. O., Persson I., Bergström R., Krusemo U. B. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989 Aug;130(2):221–228. doi: 10.1093/oxfordjournals.aje.a115328. [DOI] [PubMed] [Google Scholar]
  3. Bernier M., Hearse D. J., Manning A. S. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart. Circ Res. 1986 Mar;58(3):331–340. doi: 10.1161/01.res.58.3.331. [DOI] [PubMed] [Google Scholar]
  4. Betteridge D. J., Dodson P. M., Durrington P. N., Hughes E. A., Laker M. F., Nicholls D. P., Rees J. A., Seymour C. A., Thompson G. R., Winder A. F. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. doi: 10.1136/pgmj.69.811.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  6. Blann A., Midgley H., Burrows G., Maxwell S., Utting S., Davies M., Waite M., McCollum C. Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis. 1993 Oct;4(10):905–910. doi: 10.1097/00019501-199310000-00010. [DOI] [PubMed] [Google Scholar]
  7. Bolton-Smith C., Woodward M., Tunstall-Pedoe H. The Scottish Heart Health Study. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. II. The antioxidant vitamins and fibre. Eur J Clin Nutr. 1992 Feb;46(2):85–93. [PubMed] [Google Scholar]
  8. Bourne T., Hillard T. C., Whitehead M. I., Crook D., Campbell S. Oestrogens, arterial status, and postmenopausal women. Lancet. 1990 Jun 16;335(8703):1470–1471. doi: 10.1016/0140-6736(90)91505-5. [DOI] [PubMed] [Google Scholar]
  9. Braunwald E., Kloner R. A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982 Dec;66(6):1146–1149. doi: 10.1161/01.cir.66.6.1146. [DOI] [PubMed] [Google Scholar]
  10. Brown M. S., Goldstein J. L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223–261. doi: 10.1146/annurev.bi.52.070183.001255. [DOI] [PubMed] [Google Scholar]
  11. Bush P. J., Iannotti R. J., Zuckerman A. E., O'Brien R. W., Smith S. A. Relationships among black families' cardiovascular disease risk factors. Prev Med. 1991 Jul;20(4):447–461. doi: 10.1016/0091-7435(91)90043-4. [DOI] [PubMed] [Google Scholar]
  12. Cairns J. A., Gent M., Singer J., Finnie K. J., Froggatt G. M., Holder D. A., Jablonsky G., Kostuk W. J., Melendez L. J., Myers M. G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. doi: 10.1056/NEJM198511283132201. [DOI] [PubMed] [Google Scholar]
  13. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  14. Ceriello A., Giugliano D., Quatraro A., Lefebvre P. J. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci (Lond) 1991 Dec;81(6):739–742. doi: 10.1042/cs0810739. [DOI] [PubMed] [Google Scholar]
  15. Coghlan J. G., Flitter W. D., Holley A. E., Norell M., Mitchell A. G., Ilsley C. D., Slater T. F. Detection of free radicals and cholesterol hydroperoxides in blood taken from the coronary sinus of man during percutaneous transluminal coronary angioplasty. Free Radic Res Commun. 1991;14(5-6):409–417. doi: 10.3109/10715769109093429. [DOI] [PubMed] [Google Scholar]
  16. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  17. Colditz G. A., Stampfer M. J., Willett W. C., Hennekens C. H., Rosner B., Speizer F. E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990 Nov 28;264(20):2648–2653. [PubMed] [Google Scholar]
  18. Coope J., Warrender T. S. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1145–1151. doi: 10.1136/bmj.293.6555.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Davies S. W., Ranjadayalan K., Wickens D. G., Dormandy T. L., Timmis A. D. Lipid peroxidation associated with successful thrombolysis. Lancet. 1990 Mar 31;335(8692):741–743. doi: 10.1016/0140-6736(90)90866-4. [DOI] [PubMed] [Google Scholar]
  20. Dellsperger K. C., Martins J. B., Clothier J. L., Marcus M. L. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta-adrenergic blockade. Circulation. 1990 Sep;82(3):941–950. doi: 10.1161/01.cir.82.3.941. [DOI] [PubMed] [Google Scholar]
  21. Dupont W. D., Page D. L. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991 Jan;151(1):67–72. [PubMed] [Google Scholar]
  22. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302. doi: 10.1056/NEJM199108013250501. [DOI] [PubMed] [Google Scholar]
  23. Erbel R., Pop T., Meinertz T., Olshausen K. V., Treese N., Henrichs K. J., Schuster C. J., Rupprecht H. J., Schlürmann W., Meyer J. Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J. 1988 Mar;115(3):529–538. doi: 10.1016/0002-8703(88)90800-9. [DOI] [PubMed] [Google Scholar]
  24. Esterbauer H., Gebicki J., Puhl H., Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992 Oct;13(4):341–390. doi: 10.1016/0891-5849(92)90181-f. [DOI] [PubMed] [Google Scholar]
  25. Ferrari R., Visioli O. Calcium channel blockers and ischaemic heart disease: theoretical expectations and clinical experience. Eur Heart J. 1991 Dec;12 (Suppl F):18–24. doi: 10.1093/eurheartj/12.suppl_f.18. [DOI] [PubMed] [Google Scholar]
  26. Fletcher A., Beevers D. G., Bulpitt C., Butler A., Coles E. C., Hunt D., Munro-Faure A. D., Newson R. B., O'Riordan P. W., Petrie J. C. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988 Dec;2(4):219–227. [PubMed] [Google Scholar]
  27. Fonarow G. C., Chelimsky-Fallick C., Stevenson L. W., Luu M., Hamilton M. A., Moriguchi J. D., Tillisch J. H., Walden J. A., Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992 Mar 15;19(4):842–850. doi: 10.1016/0735-1097(92)90529-v. [DOI] [PubMed] [Google Scholar]
  28. Frankel E. N., Kanner J., German J. B., Parks E., Kinsella J. E. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet. 1993 Feb 20;341(8843):454–457. doi: 10.1016/0140-6736(93)90206-v. [DOI] [PubMed] [Google Scholar]
  29. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  30. Frishman W. H., Christodoulou J., Weksler B., Smithen C., Killip T., Scheidt S. Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J. 1978 Feb;95(2):169–179. doi: 10.1016/0002-8703(78)90460-x. [DOI] [PubMed] [Google Scholar]
  31. Gey K. F., Puska P., Jordan P., Moser U. K. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991 Jan;53(1 Suppl):326S–334S. doi: 10.1093/ajcn/53.1.326S. [DOI] [PubMed] [Google Scholar]
  32. Gibson R. S., Boden W. E., Theroux P., Strauss H. D., Pratt C. M., Gheorghiade M., Capone R. J., Crawford M. H., Schlant R. C., Kleiger R. E. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986 Aug 14;315(7):423–429. doi: 10.1056/NEJM198608143150704. [DOI] [PubMed] [Google Scholar]
  33. Goldhaber J. I., Weiss J. N. Oxygen free radicals and cardiac reperfusion abnormalities. Hypertension. 1992 Jul;20(1):118–127. doi: 10.1161/01.hyp.20.1.118. [DOI] [PubMed] [Google Scholar]
  34. Goldstein J. L., Hazzard W. R., Schrott H. G., Bierman E. L., Motulsky A. G. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 1973 Jul;52(7):1533–1543. doi: 10.1172/JCI107331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Henderson B. E., Paganini-Hill A., Ross R. K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991 Jan;151(1):75–78. [PubMed] [Google Scholar]
  36. Hertog M. G., Feskens E. J., Hollman P. C., Katan M. B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993 Oct 23;342(8878):1007–1011. doi: 10.1016/0140-6736(93)92876-u. [DOI] [PubMed] [Google Scholar]
  37. Hine L. K., Laird N. M., Hewitt P., Chalmers T. C. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA. 1989 Dec 1;262(21):3037–3040. [PubMed] [Google Scholar]
  38. Hirvonen E., Mälkönen M., Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 1981 Mar 5;304(10):560–563. doi: 10.1056/NEJM198103053041002. [DOI] [PubMed] [Google Scholar]
  39. Horton R. tPA fast by GUSTO. Lancet. 1993 May 8;341(8854):1188–1188. doi: 10.1016/0140-6736(93)91011-a. [DOI] [PubMed] [Google Scholar]
  40. Julian D. G., Prescott R. J., Jackson F. S., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982 May 22;1(8282):1142–1147. doi: 10.1016/s0140-6736(82)92225-5. [DOI] [PubMed] [Google Scholar]
  41. Kannel W. B., Abbott R. D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984 Nov 1;311(18):1144–1147. doi: 10.1056/NEJM198411013111802. [DOI] [PubMed] [Google Scholar]
  42. Kaplan J. R., Manuck S. B., Adams M. R., Clarkson T. B. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J. 1987 Sep;8(9):928–944. doi: 10.1093/oxfordjournals.eurheartj.a062370. [DOI] [PubMed] [Google Scholar]
  43. Kaplan J. R., Manuck S. B., Adams M. R., Weingand K. W., Clarkson T. B. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation. 1987 Dec;76(6):1364–1372. doi: 10.1161/01.cir.76.6.1364. [DOI] [PubMed] [Google Scholar]
  44. Keogh A. M., Schroeder J. S. A review of calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol. 1990;16 (Suppl 6):S28–S35. [PubMed] [Google Scholar]
  45. Kincaid-Smith P. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein. J Hum Hypertens. 1989 Dec;3 (Suppl 2):75–83. [PubMed] [Google Scholar]
  46. Kloner R. A., Przyklenk K., Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation. 1989 Nov;80(5):1115–1127. doi: 10.1161/01.cir.80.5.1115. [DOI] [PubMed] [Google Scholar]
  47. Leren P. Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. Am J Med. 1987 Jan 5;82(1A):31–35. doi: 10.1016/0002-9343(87)90141-0. [DOI] [PubMed] [Google Scholar]
  48. Lerner D. J., Kannel W. B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986 Feb;111(2):383–390. doi: 10.1016/0002-8703(86)90155-9. [DOI] [PubMed] [Google Scholar]
  49. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  50. Lobo R. A. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991 Nov;73(5):925–930. doi: 10.1210/jcem-73-5-925. [DOI] [PubMed] [Google Scholar]
  51. Manson J. E., Stampfer M. J., Colditz G. A., Willett W. C., Rosner B., Speizer F. E., Hennekens C. H. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991 Jul 24;266(4):521–527. [PubMed] [Google Scholar]
  52. McCord J. M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985 Jan 17;312(3):159–163. doi: 10.1056/NEJM198501173120305. [DOI] [PubMed] [Google Scholar]
  53. McGill H. C., Jr Sex steroid hormone receptors in the cardiovascular system. Postgrad Med. 1989 Apr;Spec No:64–90. [PubMed] [Google Scholar]
  54. Muller J. E., Morrison J., Stone P. H., Rude R. E., Rosner B., Roberts R., Pearle D. L., Turi Z. G., Schneider J. F., Serfas D. H. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 1984 Apr;69(4):740–747. doi: 10.1161/01.cir.69.4.740. [DOI] [PubMed] [Google Scholar]
  55. Nabulsi A. A., Folsom A. R., White A., Patsch W., Heiss G., Wu K. K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993 Apr 15;328(15):1069–1075. doi: 10.1056/NEJM199304153281501. [DOI] [PubMed] [Google Scholar]
  56. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10045–10048. doi: 10.1073/pnas.88.22.10045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Olsson G., Tuomilehto J., Berglund G., Elmfeldt D., Warnold I., Barber H., Eliasson K., Jastrup B., Karatzas N., Leer J. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. Am J Hypertens. 1991 Feb;4(2 Pt 1):151–158. doi: 10.1093/ajh/4.2.151. [DOI] [PubMed] [Google Scholar]
  58. Olsson G., Wikstrand J., Warnold I., Manger Cats V., McBoyle D., Herlitz J., Hjalmarson A., Sonneblick E. H. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992 Jan;13(1):28–32. doi: 10.1093/oxfordjournals.eurheartj.a060043. [DOI] [PubMed] [Google Scholar]
  59. Opie L. H. Reperfusion injury and its pharmacologic modification. Circulation. 1989 Oct;80(4):1049–1062. doi: 10.1161/01.cir.80.4.1049. [DOI] [PubMed] [Google Scholar]
  61. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11;327(6122):524–526. doi: 10.1038/327524a0. [DOI] [PubMed] [Google Scholar]
  62. Parker G. W., Michael L. H., Hartley C. J., Skinner J. E., Entman M. L. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res. 1990 Feb;66(2):259–270. doi: 10.1161/01.res.66.2.259. [DOI] [PubMed] [Google Scholar]
  63. Petitti D. B., Perlman J. A., Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol. 1987 Sep;70(3 Pt 1):289–293. [PubMed] [Google Scholar]
  64. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. doi: 10.1136/bmj.296.6618.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  66. Pollare T., Lithell H., Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989 Sep 28;321(13):868–873. doi: 10.1056/NEJM198909283211305. [DOI] [PubMed] [Google Scholar]
  67. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26;265(24):3255–3264. [PubMed] [Google Scholar]
  68. Psaty B. M., Koepsell T. D., LoGerfo J. P., Wagner E. H., Inui T. S. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA. 1989 Apr 14;261(14):2087–2094. [PubMed] [Google Scholar]
  69. Ramsay L. E., Yeo W. W., Jackson P. R. Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991 Oct 19;303(6808):953–957. doi: 10.1136/bmj.303.6808.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Riemersma R. A., Wood D. A., Macintyre C. C., Elton R. A., Gey K. F., Oliver M. F. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet. 1991 Jan 5;337(8732):1–5. doi: 10.1016/0140-6736(91)93327-6. [DOI] [PubMed] [Google Scholar]
  71. Rimm E. B., Stampfer M. J., Ascherio A., Giovannucci E., Colditz G. A., Willett W. C. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993 May 20;328(20):1450–1456. doi: 10.1056/NEJM199305203282004. [DOI] [PubMed] [Google Scholar]
  72. Salonen J. T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J. L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992 Apr 11;339(8798):883–887. doi: 10.1016/0140-6736(92)90926-t. [DOI] [PubMed] [Google Scholar]
  73. Schneider W., Kober G., Roebruck P., Noack H., Alle M., Cieslinski G., Reifart N., Kaltenbach M. Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists? Eur J Clin Pharmacol. 1990;39 (Suppl 1):S17–S23. [PubMed] [Google Scholar]
  74. Schreiber T. L., Miller D. H., Silvasi D., McNulty A., Zola B. E. Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990 Jun;119(6):1238–1244. doi: 10.1016/s0002-8703(05)80170-x. [DOI] [PubMed] [Google Scholar]
  75. Sies H. Strategies of antioxidant defense. Eur J Biochem. 1993 Jul 15;215(2):213–219. doi: 10.1111/j.1432-1033.1993.tb18025.x. [DOI] [PubMed] [Google Scholar]
  76. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990 Jul 19;323(3):147–152. doi: 10.1056/NEJM199007193230302. [DOI] [PubMed] [Google Scholar]
  77. Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991 Sep 12;325(11):756–762. doi: 10.1056/NEJM199109123251102. [DOI] [PubMed] [Google Scholar]
  78. Stampfer M. J., Hennekens C. H., Manson J. E., Colditz G. A., Rosner B., Willett W. C. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993 May 20;328(20):1444–1449. doi: 10.1056/NEJM199305203282003. [DOI] [PubMed] [Google Scholar]
  79. Steinbeck G., Andresen D., Bach P., Haberl R., Oeff M., Hoffmann E., von Leitner E. R. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med. 1992 Oct 1;327(14):987–992. doi: 10.1056/NEJM199210013271404. [DOI] [PubMed] [Google Scholar]
  80. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  81. Surawicz B. Prognosis of ventricular arrhythmias in relation to sudden cardiac death: therapeutic implications. J Am Coll Cardiol. 1987 Aug;10(2):435–447. doi: 10.1016/s0735-1097(87)80030-x. [DOI] [PubMed] [Google Scholar]
  82. Walsh B. W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F. M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–1204. doi: 10.1056/NEJM199110243251702. [DOI] [PubMed] [Google Scholar]
  83. Waters D., Lespérance J., Francetich M., Causey D., Théroux P., Chiang Y. K., Hudon G., Lemarbre L., Reitman M., Joyal M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990 Dec;82(6):1940–1953. doi: 10.1161/01.cir.82.6.1940. [DOI] [PubMed] [Google Scholar]
  84. Wenger N. K., Speroff L., Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993 Jul 22;329(4):247–256. doi: 10.1056/NEJM199307223290406. [DOI] [PubMed] [Google Scholar]
  85. Wiersinga W. M., Trip M. D., van Beeren M. H., Plomp T. A., Oosting H. An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship. Ann Intern Med. 1991 Jan 15;114(2):128–132. doi: 10.7326/0003-4819-114-2-128. [DOI] [PubMed] [Google Scholar]
  86. Wikstrand J., Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988 Apr 1;259(13):1976–1982. [PubMed] [Google Scholar]
  87. Wikstrand J., Warnold I., Tuomilehto J., Olsson G., Barber H. J., Eliasson K., Elmfeldt D., Jastrup B., Karatzas N. B., Leer J. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension. 1991 Apr;17(4):579–588. doi: 10.1161/01.hyp.17.4.579. [DOI] [PubMed] [Google Scholar]
  88. Wilhelmsen L., Berglund G., Elmfeldt D., Fitzsimons T., Holzgreve H., Hosie J., Hörnkvist P. E., Pennert K., Tuomilehto J., Wedel H. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987 Oct;5(5):561–572. doi: 10.1097/00004872-198710000-00009. [DOI] [PubMed] [Google Scholar]
  89. Ylä-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086–1095. doi: 10.1172/JCI114271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES